R. Bjordahl

发表

Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.

Paul C. Rogers, Cheng-Ying Wu, Bin Zhang, 2021, Cell stem cell.

Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity.

Paul C. Rogers, D. Kaufman, Jeffrey S. Miller, 2019, Blood.

Expression of the p60 Autolysin Enhances NK Cell Activation and Is Required for Listeria monocytogenes Expansion in IFN-γ-Responsive Mice1

L. Lenz, R. Bjordahl, J. Humann, 2007, The Journal of Immunology.

Responsive Mice γ Expansion in IFN-Listeria monocytogenes NK Cell Activation and Is Required for Expression of the p 60 Autolysin Enhances

L. Lenz, R. Bjordahl, J. Humann, 2007 .

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.

Paul C. Rogers, Bin Zhang, Jeffrey S. Miller, 2017, Cancer research.

iNKT Cells Suppress the CD8+ T Cell Response to a Murine Burkitt’s-Like B Cell Lymphoma

P. Marrack, Y. Refaeli, L. Gapin, 2012, PloS one.

iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy

Paul C. Rogers, D. Kaufman, Raedun Clarke, 2020, Science Translational Medicine.

CD160 Activation by Herpesvirus Entry Mediator Augments Inflammatory Cytokine Production and Cytolytic Function by NK Cells

Matthew G. Macauley, Brian C. Ware, Brian C Ware, 2013, The Journal of Immunology.

Production and Cytolytic Function by NK Mediator Augments Inflammatory Cytokine CD160 Activation by Herpesvirus Entry

Matthew G. Macauley, Brian C. Ware, Brian C Ware, 2013 .

Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma

U. Höpken, A. Rehm, K. Malmberg, 2022, Nature Communications.

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

D. Kaufman, Jeffrey S. Miller, K. Malmberg, 2019, Blood.

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

D. Kaufman, Jeffrey S. Miller, K. Malmberg, 2019, Blood.

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma

U. Höpken, A. Rehm, Bahram Valamehr, 2019, Blood.

470 Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors

Jeffrey S. Miller, D. Vallera, Bahram Valamehr, 2020 .

Lymphotoxin network pathways shape the tumor microenvironment.

R. Gascoyne, C. Steidl, C. Ware, 2013, Current opinion in immunology.

Abstract 3574: Cytokine-autonomous, CAR-directed, off-the-shelf natural killer cells derived from a clonal engineered master pluripotent cell line

D. Kaufman, Bahram Valamehr, S. Mahmood, 2018, Immunology.

Anti-NKG2C/IL-15/anti-CD33 Killer Engager Directs Primary and iPSC-derived NKG2C+ NK cells to Specifically Target Myeloid Leukemia.

Jeffrey S. Miller, K. Malmberg, D. Vallera, 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Hong Wang, Bryan M. Hancock, Bahram Valamehr, 2022, Blood.

Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.

Bahram Valamehr, Z. Davis, A. Witty, 2022, Blood.

117 FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy

Shohreh H Sikaroodi, Paul C. Rogers, Raedun Clarke, 2021, Journal for ImmunoTherapy of Cancer.

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

U. Höpken, A. Rehm, Jeffrey S. Miller, 2020 .

A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.

Shohreh H Sikaroodi, K. Wucherpfennig, Tianhao Xu, 2023, Med.

Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Matthieu Bauer, Raedun Clarke, Bahram Valamehr, 2017 .

204 Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity

Shohreh H Sikaroodi, Bryan M. Hancock, J. Powderly, 2022, Regular and Young Investigator Award Abstracts.

Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma

Sajid Mahmood, Brian Groff, Bahram Valamehr, 2021, Immunology.

Abstract 1539: Development of off-the-shelf B7H3 chimeric antigen receptor NK cell therapeutic with broad applicability across many solid tumors

Bahram Valamehr, Z. Davis, S. Gaidarova, 2021, Immunology.

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

D. Kaufman, Jeffrey S. Miller, Bahram Valamehr, 2018, Blood.

Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection

K. Malmberg, Q. Hammer, Bahram Valamehr, 2021, Blood.

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Paul C. Rogers, Jeffrey S. Miller, M. Ge, 2020 .

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Paul C. Rogers, Jeffrey S. Miller, Bahram Valamehr, 2020 .

169 Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo

Paul C. Rogers, Clark C. Chen, M. Ge, 2021, Journal for ImmunoTherapy of Cancer.

Abstract 3576: FT500, an off-the-shelf NK cell cancer immunotherapy derived from a master pluripotent cell line, enhances T-cell activation and recruitment to overcome checkpoint blockade resistance

Paul C. Rogers, Raedun Clarke, M. Ge, 2018, Immunology.

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.

Paul C. Rogers, Bin Zhang, Jeffrey S. Miller, 2017, Cancer research.

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

D. Kaufman, Jeffrey S. Miller, Bahram Valamehr, 2018, Blood.

iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma

Bahram Valamehr, Z. Davis, Robert Hullsiek, 2024, Frontiers in immunology.

iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting

Bahram Valamehr, Z. Davis, Jianming Wu, 2023, Journal for ImmunoTherapy of Cancer.